Zornitzki T, Malnick S, Lysyy L, Knobler H. Interferon therapy in hepatitis C leading to chronic type 1 diabetes. World J Gastroenterol 2015; 21(1): 233-239 [PMID: 25574096 DOI: 10.3748/wjg.v21.i1.233]
Corresponding Author of This Article
Stephen Malnick, MA, MSc, MBBS, Director, Department of Gastroenterology, Hebrew University Medical School, Kaplan Medical Center, HaGalil St 5, Rehovot 76100, Israel. stephen@malnick.net
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Jan 7, 2015; 21(1): 233-239 Published online Jan 7, 2015. doi: 10.3748/wjg.v21.i1.233
Interferon therapy in hepatitis C leading to chronic type 1 diabetes
Taiba Zornitzki, Stephen Malnick, Lyudmila Lysyy, Hilla Knobler
Taiba Zornitzki, Lyudmila Lysyy, Hilla Knobler, Department of Diabetes, Metabolism and Endocrinology, Hebrew University Medical School, Kaplan Medical Center, Rehovot 76100, Israel
Stephen Malnick, Department of Gastroenterology, Hebrew University Medical School, Kaplan Medical Center, Rehovot 76100, Israel
Author contributions: Zornitzki T, Malnick S and Knobler H designed the research; Zornitzki T and Knobler H reviewed and analyzed the interferon-induced type 1 diabetes literature; Lysyy L evaluated and wrote the case report; Zornitzki T, Malnick S and Knobler H wrote the manuscript.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Stephen Malnick, MA, MSc, MBBS, Director, Department of Gastroenterology, Hebrew University Medical School, Kaplan Medical Center, HaGalil St 5, Rehovot 76100, Israel. stephen@malnick.net
Telephone: +972-8-9441852 Fax: +972-8-9441852
Received: March 28, 2014 Peer-review started: March 29, 2014 First decision: April 15, 2014 Revised: July 20, 2014 Accepted: July 24, 2014 Article in press: July 25, 2014 Published online: January 7, 2015 Processing time: 284 Days and 12.1 Hours
Core Tip
Core tip: Interferon (INF) treatment is an important component of hepatitis C virus treatment. Although INF-associated type 1 diabetes mellitus was described more than 2 decades ago its importance is under-recognized. Based on a review of all published cases we found that this complication typically appears abruptly, is manifested by severe hyperglycemia accompanied by a high titer of anti-islet antibodies and is often associated with autoimmune thyroid disease. Most worrisome, almost all patients who develop this complication require permanent insulin treatment. With the emergence of new interferon-free therapies, this serious complication has to be taken into consideration especially in relatively young patients with mild to moderate disease.
